U.S. Drug Spending Will Increase 7.6% in 2015, Including PCSK9 Costs – CMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency expects PCSK9 drugs for cholesterol will have relatively “modest” impact on drug spending across commercial and government payers in 2015, actuaries explain.
You may also be interested in...
US Retail Drug Spending Growth Slowing With No New Sovaldis In Sight
Rate of growth in prescription drug spending is expected to average 6.7% per year from 2016 through 2025, National Health Expenditures report from CMS projects.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.